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Clonal Complex 258, the Most Frequently Found Multilocus Sequence
Type Complex in KPC-2-Producing Klebsiella pneumoniae Isolated in
Brazilian Hospitals
We read with great interest the article by Andrade et al. (1)describing the predominance of sequence type 258 (ST258)
among KPC-2-producingKlebsiella pneumoniae isolates in Brazil-
ian hospitals. Recently, we conducted a similar study that evalu-
ated the genetic relationship among KPC-2-producing K. pneu-
moniae isolates from Brazilian hospitals.
A total of 34 KPC-2-producing K. pneumoniae isolates were
collected from 13 distinct hospitals located at seven Brazilian
states during the period of 2008 to 2010 and referred to Labo-
ratório Alerta, UNIFESP, for further characterization. A single
isolate per patient was analyzed. Antimicrobial susceptibility test-
ing was performed and interpreted using the CLSI agar dilution
(M100-S22) method for all agents except polymyxin B, for which
the EUCAST criteria for colistin were applied (2, 4). The presence
of the blaKPC-2 gene was confirmed by PCR, followed by sequenc-
ing (5). Genetic relationship among KPC-2-producing isolates
was assessed by multilocus sequence typing (MLST) and pulsed-
field gel electrophoresis (PFGE), using SpeI as the restriction en-
zyme (3, 7).
The antimicrobial susceptibility profile of the isolates is pre-
sented in Table 1. All isolates were resistant to ertapenem, while
44.1% and 23.5% remained susceptible to imipenem and
meropenem, respectively. Among the 34 KPC-2 producers,
seven STs were observed, including the new ST ST617 (Table
1). In contrast to the results reported by Andrade et al. (1),
ST258 itself was not identified among the isolates studied, but
STs related to clonal complex 258 (CC258), ST437, and ST11
were observed. ST437 was the most frequently detected ST (18
isolates; 52.9%) and was isolated from seven medical centers in
two Brazilian states, while ST11 was the most widely distrib-
uted. ST11 was detected in 10 (29.4%) isolates collected from
eight hospitals located in five distinct states (Table 1). Interest-
ingly, ST11 isolates showed a greater degree of variability by
PFGE (six PFGE patterns) than ST437, which was grouped un-
der a single PFGE pattern.
Single representatives of ST133, ST340, and ST617 were found
among isolates collected from distinct hospitals located in the
same city. Of notice, only strains belonging to ST11 and ST437
showed imipenem and meropenem resistance, whereas reduced
susceptibility to polymyxin B was observed in seven (20.6%) iso-
lates that belonged to three PFGE patterns: A (5 isolates), C, and
H. These PFGE patterns were grouped under four STs, ST11 (2
isolates), ST17, ST133, and ST437 (3 isolates).
In the study by Andrade et al. (1), ST258 was the most
frequently reported ST among KPC-2-producing K. pneu-
moniae isolates. However, these authors have studied only K.
pneumoniae isolates collected from two Brazilian states (São
Paulo and Rio de Janeiro). In our study, we included strains
isolated from São Paulo and six other Brazilian states (Distrito
Federal, Mato Grosso do Sul, Minas Gerais, Paraíba, Pernam-
buco, and Rio Grande do Sul). Despite the identification of
novel STs, we observed the predominance of ST437, which is a
single-locus variant of ST258, among Brazilian isolates. Our
results corroborate the initial findings regarding the predomi-
nance of CC258 among KPC-2-producing K. pneumoniae iso-
lates (6). These data suggest that KPC-2-producing isolates
originated from a common ancestor derived from ST258,
which has undergone genetic evolution. These findings point
out that horizontal acquisition of blaKPC-2 by genetically unre-
lated strains has contributed to the dissemination of KPC-2-
producing isolates throughout Brazilian territory, but hospital
outbreaks caused by single clones have also influenced the in-
creased frequency of ST437 isolation observed in this study.
(Part of this study was presented at the 51st Interscience Con-
ference on Antimicrobial Agents and Chemotherapy, Chicago, IL,
17 to 20 September 2011.)
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